Josh Rising

Josh Rising

  • Director
  • Medical Devices,
  • The Pew Charitable Trusts


Dr. Josh Rising directs Pew's medical device initiative, which seeks to facilitate innovation of certain new medical devices and to strengthen medical devices by improving the tracking of their safety once they are on the market.

Before joining Pew, Rising helped establish the Office of Policy in the Food and Drug Administration’s Center for Tobacco Products.  He also served as health policy analyst for the Connecticut legislature, with a focus on issues of healthcare access, Medicaid policy, health IT and healthcare quality.  He also served as legislative affairs director for the American Medical Student Association (AMSA). 

He received his M.D. and his M.P.H. at Boston University, completed his pediatric residency at the University of California, San Francisco and trained for a year as a Robert Wood Johnson Clinical Scholar at Yale University.  He has published in peer-reviewed literature on, among other topics, children with special health care needs and the expansion of a county-run health insurance program.

Recent Work

View All
  • Pew Testimony on the Use of Unique Device Identifiers in Health Insurance Claims

    On June 10, the U.S. Department of Health and Human Services’ National Committee on Vital and Health Statistics, Subcommittee on Standards, held a hearing that discussed the incorporation and use of unique device identifiers (UDI) in administrative transactions. Josh Rising, director of drugs and medical devices, submitted testimony on the importance of including UDIs in health insurance... Read More

  • The Hill: Coming Soon: IDs to Track Medical Devices

    Congressional hearings on health care can be contentious, but the story will be different today (November 19), when the bipartisan House Medical Technology Caucus convenes a forum with representatives from the U.S. Food and Drug Administration , manufacturers, and hospitals to discuss how new tracking codes for medical devices can enhance recalls and assessments of heart stents, glucose monitors,... Read More

  • ''Delays and Difficulties in Assessing Metal-on-Metal Hip Implants''

    More than 500,000 U.S. patients have received metal-on-metal hip prostheses, most of which were implanted between 2003 and 2010. These prostheses entered the market through the 510(k) pathway at the Food and Drug Administration (FDA), whereby manufacturers need only demonstrate substantial equivalence to a device already on the market to gain approval. Unfortunately, there is now compelling... Read More

Media Contact

Arlyn Riskind

Manager, Communications